> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# ICH Q&A Document for Drug Quality Guidelines
- URL: https://www.fdaweb.com/ich-q-a-document-for-drug-quality-guidelines/
- Published: 2026-05-29T12:00:00.000Z
- Updated: 2026-09-14T13:40:11.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161225

The International Council for Harmonization has updated its long-running question-and-answer guidance tied to the ICH Q8, Q9 and Q10 pharmaceutical quality guidelines, adding new detail on real-time release testing, pharmaceutical quality systems and the role of knowledge management in modern drug manufacturing.

The revised [Q&A document](https://www.fda.gov/media/78668/download?ref=fdaweb.com), designated R5, includes multiple updates approved in 2024 that clarify regulatory expectations around quality-by-design (QbD), control strategies and advanced manufacturing oversight.

Among the most significant additions are new explanations of real-time release testing (RTRT), which ICH describes as the use of process data and in-process controls to assure product quality in place of relying solely on end-product testing.

ICH said RTRT should be considered part of a broader control strategy and may involve in-line, on-line or at-line testing of critical quality attributes during manufacturing. The guidance states that RTRT approaches can provide greater assurance of product quality than traditional end-product testing under certain conditions.

The document also makes clear that failed RTRT results generally cannot be overridden through conventional finished-product testing to release a batch. Instead, manufacturers are expected to investigate failures and make release decisions consistent with good manufacturing practice requirements and marketing authorizations.

The updated guidance further clarifies that parametric release — commonly used for sterilization processes — is considered a form of RTRT because it relies on process parameters rather than direct testing of finished product samples.

ICH also expanded discussion of pharmaceutical quality systems under ICH’s Q10, highlighting benefits such as reduced recall risk, improved process performance, more efficient regulatory oversight and greater manufacturing consistency across global markets.

According to the guidance, companies implementing robust pharmaceutical quality systems may achieve “greater assurance of compliance with GMP,” potentially leading to shorter inspections and enhanced regulator confidence in product quality.

The document reiterates that companies are not required to include a full description of their pharmaceutical quality system in regulatory submissions, though elements such as change management and quality monitoring systems may be referenced as supporting information.

ICH additionally emphasized that no formal certification exists for compliance with ICH Q10 standards and that regulators do not require companies to maintain formalized knowledge management systems or purchase commercial software marketed as “ICH-compliant.”

However, the guidance stresses that firms are expected to effectively use manufacturing and development knowledge throughout a product’s lifecycle, particularly as companies adopt more complex manufacturing approaches involving process analytical technology, real-time monitoring and advanced data systems.

The updated Q&A also outlines how inspections may evolve in an ICH Q8, Q9 and Q10 environment, with regulators placing greater emphasis on process understanding, quality risk management and the operation of approved design spaces during manufacturing. ICH said inspections in advanced manufacturing settings may require closer collaboration between inspectors and application assessors, particularly for products involving complex development data and enhanced process controls.